Jörgen Ekström
Corporate Officer/Principal at University of Gothenburg
Jörgen Ekström active positions
Companies | Position | Start | End |
---|---|---|---|
University of Gothenburg | Corporate Officer/Principal | 2011-01-23 | - |
Career history of Jörgen Ekström
Former positions of Jörgen Ekström
Companies | Position | Start | End |
---|---|---|---|
University of Lund | Corporate Officer/Principal | - | - |
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Director/Board Member | 2009-11-30 | - |
Founder | 2009-11-30 | - |
Statistics
International
Sweden | 4 |
Operational
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Founder | 1 |
Sectoral
Consumer Services | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Health Technology |
- Stock Market
- Insiders
- Jörgen Ekström
- Experience